Dr. Stephen Hahn addressed the role of the U.S. Food and Drug Administration in the COVID-19 response and best practices and lessons learned from the emergency response to date.
This briefing explored how our supply chain must respond to manufacture millions of doses and then swiftly deliver them to administration sites. Panelists also illustrated the steps these stakeholders might take in the first 48 hours after an Emergency Use Authorization is approved.
This discussion focused on measures industry stakeholders have taken for safe COVID-19 vaccine deployment and the immediate steps these stakeholders will take in the first 48 hours after the Emergency Use Authorization was approved.
During this webinar, panelists explored the impact of the pandemic on different facets of the drug supply chain and discussed policy options to strengthen the system.
There is no excerpt because this is a protected post.
During this on-the-record briefing for reporters, Admiral Brett P. Giroir, M.D., Assistant Secretary for Health at the U.S. Department of Health and Human Services, provided opening remarks and responded to questions from reporters.
During this on-the-record briefing for reporters, Joe Grogan, Assistant to the President and Director of the Domestic Policy Council provided opening remarks and responded to questions from reporters. The question and answer period was moderated by William Pierce, Senior Director, APCO Worldwide.
During this congressional lunch briefing, analysts will outline the mechanisms of the Medicare Part D program under current law and discuss the potential implications of reforms put forward by Congress and the administration.
During this briefing, panelists will discuss components of policy proposals under consideration and explore evidence about their implications for the health care system.
During this webinar, analysts discussed the outstanding legislative and regulatory activities that Congress and the administration are likely to pursue before the end of the year.
During this webinar, panelists explored the relationship between patents, prices, and patient access.
There is no excerpt because this is a protected post.
During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discuss considerations for the biosimilars market in the United States.
The audience will come away with a better understanding of the origins of the rebate system, the actors responsible for negotiation, and the impact of rebates on prescription drug prices.
This webinar will focus on the first approach and will explore different perspectives on how increasing the number of generic and biosimilar options may affect the drug pricing market. Specifically, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.
This exclusive reporter briefing featured FDA Commissioner Scott Gottlieb, M.D., followed by a panel of industry leaders and stakeholders responding to new drug pricing guidance.
The purpose of this briefing was to orient federal policymakers and stakeholders to the legislative and regulatory actions that state officials are perusing to address the rising cost of prescription drugs in Medicaid. Panelists outlined the rationale for these actions, detailed the mechanisms of state policies, and described opportunities to leverage flexibility within federal parameters.
The opioid addiction crisis has thrown a spotlight on the physical and behavioral health issues surrounding chronic pain. This briefing examined innovative non-pharmacologic models to address chronic pain, including among the military and veteran population and through state Medicaid and safety net programs.
This Alliance for Health Policy briefing discussed current issues in prescription drug affordability and innovation, focusing on potential policy and private-sector approaches to this complex issue.
This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.
With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.
Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs. As a response to price increases of both single-source and generic drugs, some stakeholders are calling for a move towards basing payments on value, and some payers and pharmaceutical manufacturers are exploring ways to base payments on outcomes. However, many challenges remain.
A top Federal Trade Commission official, along with key experts, met with reporters Dec. 15 to discuss the recent surge in health care consolidation; the driving forces behind this trend; and the implications for policymakers and enforcers.
In 2014, there were a total of 1,299 mergers and acquisitions in the health care sector – a record number, up from 1,035 the year before. This briefing will discussed the driving forces behind this recent increase in consolidation; the scope and extent of consolidation among doctors, hospitals and insurers; implications for consumers and other stakeholders; and the roles of the Department of Justice and the Federal Trade Commission.